GlobeNewswire

2018 YPO EDGE Delivers Innovative and Transformative Global Idea Exchange

Dela

Business leaders from more than 130 countries focus on defying convention

 

SINGAPORE, March 12, 2018 (GLOBE NEWSWIRE) -- YPO, the premier global leadership organization of chief executives, hosted more than 2,800 business leaders from more than 130 countries at the 2018 YPO EDGE, its flagship event in Singapore this month. YPO business leaders gathered with world-renowned thought leaders and innovators to address key issues in business, politics, science, philanthropy and humanities.

Chief executives from different industries learned about unique groundbreaking approaches to challenges and opportunities in business and beyond from world leaders, philanthropists and business legends, including:

  • Lee Hsien Loong, Prime Minister of Singapore
  • Orit Gadiesh, Chairman, Bain and Company
  • Victor Fung, Ph.D., Chairman, Fung Group; Honorary Chairman, Li and Fung LTD
  • Rahul Gandhi, MP, President of the Indian National Congress
  • Datin Paduka Marina Mahathir, Author and Activist
  • Yoshi Hori, President of GLOBIS University and Managing Partner of GLOBIS Capital Partners
  • Billie Jean King, Founder of Billie Jean King Leadership Initiative and former World No.1 tennis player

"As one of Asia's fastest-growing cities, Singapore is not only recognized as a world-class destination but admired around the world for its growth and evolution, making Singapore an ideal host city for the 2018 YPO EDGE, the world's largest gathering of chief executives," said Scott Mordell, CEO of YPO. "The YPO EDGE encouraged participants to alter their paradigms to deliver significant impact within the global community in the form of economic opportunity, sustainable environmental change and compassionate leadership."

Other speakers, including Michael Fertik, CEO of Reputation.com; Mark McDonald, Co-Founder of Appster; Maura O'Neill, Ph.D., Faculty Director of UC Berkeley Executive Education and Former Chief Innovation Officer of USAID; and Pattie Sellers, Co-Founder of SellersEaston Media and Former Assistant Managing Editor of "Fortune," inspired YPO leaders to take new risks as they shared their breakthroughs in reputation and brand management, humanitarian leadership, innovative technology and more.

"The 2018 EDGE is designed to challenge business leaders from around the world to defy convention, achieve the extraordinary and enrich their personal leadership," said N.K. Tong, 2018 YPO EDGE Chair. "Now, 2,800 global business leaders will return to their home countries ready to make a difference and transform lives."

The 2018 YPO EDGE marks the second time Singapore has hosted this signature YPO leadership gathering.

"The YPO Singapore chapter and its members were honored to welcome our peers from across the globe for the YPO EDGE," said Terry O'Connor, 2018 Host City Chair. "As a regional hub, Singapore is the heart of the regional economy, and the EDGE was the perfect event to showcase the culture, diversity and areas of opportunity in Singapore and Southeast Asia to business leaders and young entrepreneurs."

Past EDGE events have been held in Vancouver, Dubai, Melbourne, Los Angeles, Istanbul, Singapore, Barcelona, Miami, Sydney, Toronto, and other major cities. Speakers at previous YPO EDGE events include Canadian Prime Minister Justin Trudeau; Sir Richard Branson, founder and chairman of the Virgin Group; Muhtar Kent, chairman and CEO of the Coca-Cola Company; Malala Yousafzai, Nobel Peace Prize laureate; and Archbishop Desmond Mpilo Tutu, Nobel Peace Prize laureate.

The 2019 YPO EDGE is slated for Cape Town, South Africa.

About YPO
The premier leadership organization of chief executives in the world.

YPO is the global platform for chief executives to engage, learn and grow. YPO members harness the knowledge, influence and trust of the world's most influential and innovative business leaders to inspire business, personal, family and community impact.

Today, YPO empowers more than 25,000 members in more than 130 countries, diversified among industries and types of businesses. Altogether, YPO member-run companies employ more than 16 million people and generate USD6 trillion in annual revenues.

Leadership. Learning. Lifelong. For more information, visit YPO.org.

Contact:
YPO
Linda Fisk
Office: +1 972 629 7305 (United States)
Mobile: +1 972 207 4298 
press@ypo.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: YPO via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum